A recent study offering a comprehensive view of the genome and transcriptome of gastrointestinal stromal tumors (GISTs) has introduced a new, multi-omics-based molecular classification of these ...

DelveInsight’s “Gastrointestinal Stromal Tumor Market Insights, Epidemiology ... as well as combined safety results from multiple clinical trials for avapritinib. Stivarga (BAY 73-4506) is the brand ...

Kura Oncology Inc. (KURA) said that it has entered into a global strategic collaboration with Kyowa Kirin Co., Ltd. to develop and ...

The C2 subtype, defined as CD8 + inflamed, comprises high-risk intestinal GISTs with high infiltration of immune cells, especially CD8 + T cells, suggesting that these tumors may benefit from a ...

Gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors and were among the first solid tumor types for which such a novel treatment (in this case imatinib) became available. The ...

Background Gastrointestinal stromal tumor (GIST) is known for its wide variability in biological behaviors and it is difficult to predict its malignant potential. The aim of this study is to ...

Huntsman Cancer Institute’s Sarcoma Service has a specialist team that treats soft-tissue sarcomas that form in the abdomen. Here are some soft-tissue sarcomas of the abdomen: Gastrointestinal stromal ...

Results from a population-based study evaluating gastrointestinal stromal tumor (GIST) patients have led researchers to propose that risk scores based solely on tumor size and proliferative index ...

A recent study offering a comprehensive view of the genome and transcriptome of gastrointestinal stromal tumors (GISTs) has introduced a new, multi-omics-based molecular classification of these ...

“Our results indicate that the combination of ziftomenib and imatinib acts via a synthetic lethal mechanism through which ziftomenib targets an epigenetic vulnerability of GIST tumors, creating ...